Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$23.12 USD
+0.11 (0.48%)
Updated Sep 19, 2025 03:59 PM ET
3-Hold of 5 3
C Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CHGCY 23.12 +0.11(0.48%)
Will CHGCY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CHGCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHGCY
Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?
Chugai Pharmaceutical Co. (CHGCY) Upgraded to Buy: Here's Why
CHGCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Other News for CHGCY
Eli Lilly upgraded at HSBC after latest trial win for obesity pill
Chugai Pharmaceutical (CHGCY) Sees Stock Surge After Eli Lilly Trial Success
Chugai spikes after Eli Lilly trial win for obesity pill
Market Today: MongoDB (MDB) Surges on Strong Q2 Results
Macquarie Healthcare Fund Q2 2025 Commentary